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Dear Dr. Thomas A. Fleischer
Editor, Journal of Clinical Immunology
We read with much enthusiasm the essay by Dr. Wingerchuk
on the plausibility for the use of IVIG in preventing relapses in
patients with NMO (Epub 2012 Sep 14), an interesting
alternative for the invasive procedure that is plasma exchange.
We would like to share with you and Dr. Wingerchuk our
work presented at this years AAN meeting, reporting the
effects of IVIG used in 8 patients with relapsing NMO
(Neurology April 22, 2012 78:P04.141). There were 7 wom-
en and one man with mean age of 30 years and mean disease
duration of 7.6 years; 5 were positive for the NMO-IgG.
Reasons for IVIG indication were either severe relapse not
improving after 5 g IV methylprednisolone and inefficacy to
reduce ARR or EDSS worsening on adequate immunosup-
pression with azathioprine and prednisone. One patient re-
ceived the drug soon after a cluster of relapses upon
diagnosis. We used the same dose as for other immune
mediated neurological diseases, i.e., 0.4 g/kg/day for 5
consecutive days, and patients received two to ten cycles
of IVIG, usually 2 months apart. We observed a mean ARR
reduction from 1.8 (±1.6) to 0.1 (±0.2) and mean PI from 1.5
(±1.6) to 0.9 (±0.6). There were no adverse effects from the
use of IVIG, but unfortunately one patient died due to severe
encephalitic and brainstem relapse while on therapy.
The rationale for using IVIG in these patients were
the same discussed by Dr. Wingerchuk, stimulated by
the fact that plasma exchange is not reimbursed by the
public health care system in Brazil for the treatment of
NMO. We understand that NMO is a rare disease, and
most of the treatment strategies remain based on case series
and expert opinion, and hope that the use of IVIG can be
further evaluated in larger series in order to prove its efficacy
as an alternative for plasma exchange, or even its use upon
diagnosis as an “induction therapy”.
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